CAT Finds the CMA Failed to Establish Excessive and Unfair Prices for Phenytoin Sodium

Click here to read the full article online

This article covers the UK Competition Appeal Tribunal (CAT) decision on 7 June 2018 setting aside in part the 2016 decision of the CMA that Pfizer and Flynn Pharma had abused their dominant positions by setting excessive and unfair prices for the capsule form of the epilepsy drug phenytoin sodium. This has important implications for other similar CMA cases in the pharma sector.